ANNOVIS BIO INC. COMMON STOCK
1.7000
12-3月-25 16:30:00
15 分の遅延
株式
+0.1000
+6.25%
本日の幅
1.5700 - 1.7200
ISIN
N/A
ソース
NYSE
-
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
06 8 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
24 7 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
16 7 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
09 7 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
27 6 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
26 6 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
25 6 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
18 6 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
11 6 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
Annovis Announces New Publication in a Peer-Reviewed Journal
21 5 2024 07:30:00 提供 Nasdaq GlobeNewswire
-
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
13 5 2024 07:30:00 提供 Nasdaq GlobeNewswire
-
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
09 5 2024 07:30:00 提供 Nasdaq GlobeNewswire
-
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
06 5 2024 07:30:00 提供 Nasdaq GlobeNewswire
-
29 4 2024 10:10:00 提供 Nasdaq GlobeNewswire
-
02 4 2024 07:30:00 提供 Nasdaq GlobeNewswire
-
01 4 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
20 3 2024 07:30:00 提供 Nasdaq GlobeNewswire
-
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
27 2 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
14 2 2024 07:30:00 提供 Nasdaq GlobeNewswire